Q&A: FDA Approves Alopecia Areata Treatment With Roots at Yale
June 14, 2022
June 14, 2022
NEW HAVEN, Connecticut, June 14 (TNStalk) -- Yale University issued the following Q&A with Brett King, associate professor of dermatology at Yale Medical School:
In a June 13 announcement, the U.S. Food and Drug Administration approved the use of the Janus kinase (JAK) inhibitor baricitinib as a treatment for severe alopecia areata, a disfiguring skin disease.
It is the first approved treatment for alopecia areata, an autoimmune disorder that affects about 7 million . . .
In a June 13 announcement, the U.S. Food and Drug Administration approved the use of the Janus kinase (JAK) inhibitor baricitinib as a treatment for severe alopecia areata, a disfiguring skin disease.
It is the first approved treatment for alopecia areata, an autoimmune disorder that affects about 7 million . . .